UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

Leukemia, 2006-02, Vol.20 (2), p.322-328

2006

Volltextzugriff (PDF)

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Leukemia, 2017-01, Vol.31 (1), p.107-114

2017

Volltextzugriff (PDF)

Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients

Human reproduction (Oxford), 2008-05, Vol.23 (5), p.1007-1013

2008

Volltextzugriff (PDF)

Bisphosphonate-Related Osteonecrosis of the Jaws: A Single-Center Study of 101 Patients

Journal of oral and maxillofacial surgery, 2009-04, Vol.67 (4), p.850-855

2009

Volltextzugriff (PDF)

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up

Leukemia, 2010-05, Vol.24 (5), p.1050-1052

2010

Volltextzugriff (PDF)

Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine busulfan

Leukemia, 2007-10, Vol.21 (10), p.2109-2116

2007

Volltextzugriff (PDF)

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

Leukemia, 2005-01, Vol.19 (1), p.7-12

2005

Volltextzugriff (PDF)

The emperor is naked: the quality of response to first-line therapy is not related to survival in multiple myeloma (MM) patients

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e164-e164

2015

Volltextzugriff (PDF)

Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug

British journal of haematology, 2000-02, Vol.108 (2), p.391-393

2000

Volltextzugriff (PDF)

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Bone marrow transplantation (Basingstoke), 2008-02, Vol.41 (4), p.355-361

2008

Volltextzugriff (PDF)

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

Leukemia, 2003-02, Vol.17 (2), p.290-297

2003

Volltextzugriff (PDF)

Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF

Bone marrow transplantation (Basingstoke), 2003-07, Vol.32 (1), p.31-34

2003

Volltextzugriff (PDF)

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma

Journal of clinical oncology, 2015-10, Vol.33 (30), p.3459-3466

2015

Volltextzugriff (PDF)

Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioview (Duet) combined morphological and cytogenetical analysis

Leukemia, 2002-08, Vol.16 (8), p.1413-1418

2002

Volltextzugriff (PDF)

Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma

Leukemia & lymphoma, 2001, Vol.42 (4), p.683-687

2001

Volltextzugriff (PDF)

Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?

Genes chromosomes & cancer, 2016-09, Vol.55 (9), p.710-718

2016

Volltextzugriff (PDF)

Overexpression of CXCR4 on human CD34+progenitors increases their proliferation, migration, and NOD/SCID repopulation

Blood, 2004-04, Vol.103 (8), p.2942-2949

2004

Volltextzugriff (PDF)

Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients

Journal of immunotherapy, 2009-05, Vol.32 (4), p.415-423

2009

Volltextzugriff (PDF)

Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders

Journal of developmental and behavioral pediatrics, 2016-10, Vol.37 (8), p.659-673

Beversdorf, David Q

2016

Volltextzugriff (PDF)

Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients

Bone marrow transplantation (Basingstoke), 1993, Vol.11 (1), p.1-5

1993

Volltextzugriff (PDF)

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

Haematologica (Roma), 2008-03, Vol.93 (3), p.455-458

2008

Volltextzugriff (PDF)

Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients

Bone marrow transplantation (Basingstoke), 2003-04, Vol.31 (8), p.655-661

2003

Volltextzugriff (PDF)

Carfilzomib (K) Vs Low-Dose Corticosteroids and Optional Cyclophosphamide (Cy) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (Rrmm): Results from a Phase 3 Study (Focus)

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

1 – 25 von 886

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(655)
Mit Volltextzugriff
(705)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(38)
... seit 30 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients

Bisphosphonate-Related Osteonecrosis of the Jaws: A Single-Center Study of 101 Patients

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

The emperor is naked: the quality of response to first-line therapy is not related to survival in multiple myeloma (MM) patients

Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma

Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioview (Duet) combined morphological and cytogenetical analysis

Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma

Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes

Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?

Overexpression of CXCR4 on human CD34+progenitors increases their proliferation, migration, and NOD/SCID repopulation

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients

Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders

Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients

Carfilzomib (K) Vs Low-Dose Corticosteroids and Optional Cyclophosphamide (Cy) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (Rrmm): Results from a Phase 3 Study (Focus)

Suchergebnisse filtern